Acta Pol Pharm
-
Randomized Controlled Trial
Calendula extract: effects on mechanical parameters of human skin.
The aim of this study was to evaluate the effects of newly formulated topical cream of Calendula officinalis extract on the mechanical parameters of the skin by using the cutometer. The Cutometer 580 MPA is a device that is designed to measure the mechanical properties of the skin in response to the application of negative pressure. This non-invasive method can be useful for objective and quantitative investigation of age related changes in skin, skin elasticity, skin fatigue, skin hydration, and evaluation of the effects of cosmetic and antiaging topical products. ⋯ These were then evaluated statistically to measure the effects produced by these creams. Using ANOVA, and t-test it was found that R0, and R6 were significant (p <0.05) whereas R1, R2, R5, R7, R8 were insignificant (p > 0.05). The instrumental measurements produced by formulation reflected significant improvements in hydration and firmness of skin.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Osteolytic bone destruction, caused by the aberrant production and activation of osteoclasts, results in significant morbidity for patients with multiple myeloma (MM). Pamidronate [(3-amino-1-hydroxypropylidene)-1,1-bis-phosphonate] inhibits osteoclastic activity and reduces bone resorption. A potency of zoledronic acid (2-[imidazol-1-yl]-1-hydroxyethylidene-1,1-bisphosphonic acid, a new third generation bisphosphonate, as inhibitor of resorption was 850-fold greater than pamidronate, as was shown in preclinical models of bone resorption. ⋯ At present actual median survival time of analysed patients since MM diagnosis is 42 months, since the beginning of treatment with pamidronate and zoledronic acid--33 months, and since completing treatment--20 months and is similar in 3 treatment groups. As was shown in our single center study in MM patients the safety and efficacy of pamidronate 90 mg and zoledronic acid 4 mg and 8 mg in monthly i.v. infusion are comparable. Thus the recommended dosage of zoledronic acid is 4 mg administered as a 15 minute i.v. infusion at intervals of 3 to 4 weeks.